A trio of hires at 4D
Plus: Madrigal hires Shannon Kelley as general counsel, and updates from NodThera, Dragonfly, AusBiotech and more
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) hired Dhaval Desai as chief development officer, Christopher Simms as chief commercial officer and Carlos Quezada-Ruiz as SVP, therapeutic area head, ophthalmology. Desai and Simms join the company from Iveric bio Inc., where Desai was SVP and CDO and Simms was SVP and CCO. Quezada-Ruiz was group medical director, clinical science, product development in the ophthalmology division at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Simms’ hiring is effective Sept. 25.
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL), which markets Rezdiffra resmetirom to treat metabolic-associated steatohepatitis (MASH), hired Shannon Kelley as general counsel. Kelley was chief compliance officer, North America and global specialty care at Sanofi (Euronext:SAN; NASDAQ:SNY)...